{"id":587188,"date":"2025-12-08T21:53:11","date_gmt":"2025-12-08T21:53:11","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/587188\/"},"modified":"2025-12-08T21:53:11","modified_gmt":"2025-12-08T21:53:11","slug":"la-liste-noire-des-medicaments-autorises-mais-a-eviter-sepaissit-de-quatre-nouveaux-produits","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/587188\/","title":{"rendered":"La liste noire des m\u00e9dicaments autoris\u00e9s mais \u00e0 \u00e9viter s\u2019\u00e9paissit de quatre nouveaux produits"},"content":{"rendered":"<p>La revue <a href=\"https:\/\/www.prescrire.org\/medicaments-et-evaluations\/medicaments-a-ecarter\" rel=\"nofollow noopener\" target=\"_blank\" class=\"c-link c-link--is-underlined\">Prescrire<\/a> publie son nouveau bilan des <a href=\"https:\/\/www.20minutes.fr\/dossier\/medicament\" target=\"_blank\" class=\"c-link c-link--is-underlined\" rel=\"noopener\">m\u00e9dicaments<\/a> \u00ab\u00a0\u00e0 \u00e9carter\u00a0\u00bb, un outil destin\u00e9 \u00e0 aider les patients \u00ab\u00a0\u00e0 choisir des soins de qualit\u00e9 et \u00e9viter des dommages disproportionn\u00e9s\u00a0\u00bb. L\u2019\u00e9dition 2026 s\u2019inscrit dans la continuit\u00e9 des pr\u00e9c\u00e9dentes\u00a0: certains traitements restent disponibles malgr\u00e9 \u00ab\u00a0une balance b\u00e9n\u00e9fices-risques d\u00e9favorable\u00a0\u00bb, ce qui conduit la revue \u00e0 rappeler que \u00ab\u00a0d\u2019autres options th\u00e9rapeutiques ont une meilleure balance\u00a0\u00bb et que, parfois, \u00ab\u00a0l\u2019option la plus prudente est de ne pas recourir \u00e0 un m\u00e9dicament\u00a0\u00bb.<\/p>\n<p>Dans cette actualisation, quatre m\u00e9dicaments rejoignent la liste\u00a0: l\u2019andexanet alfa, la chondro\u00eftine, le f\u00e9zolin\u00e9tant et le g\u00e9fapixant. Tous ont en commun d\u2019exposer les patients \u00e0 des effets ind\u00e9sirables jug\u00e9s disproportionn\u00e9s en regard d\u2019une efficacit\u00e9 absente, incertaine ou trop modeste. Pour Prescrire, cette \u00e9volution refl\u00e8te la n\u00e9cessit\u00e9 de r\u00e9examiner les preuves disponibles et de retirer de la pratique les traitements dont l\u2019int\u00e9r\u00eat clinique n\u2019est pas \u00e9tabli.<\/p>\n<\/p>\n<p>Evaluer les risques des m\u00e9dicaments<\/p>\n<p>L\u2019andexanet alfa, utilis\u00e9 comme antidote des anticoagulants mais non commercialis\u00e9 en France, augmente le risque d\u2019accidents thromboemboliques par rapport aux soins usuels. La chondro\u00eftine, prescrite dans l\u2019arthrose, peut provoquer des r\u00e9actions d\u2019hypersensibilit\u00e9. Le f\u00e9zolin\u00e9tant, indiqu\u00e9 dans les bouff\u00e9es de chaleur li\u00e9es \u00e0 la m\u00e9nopause, expose notamment \u00e0 une h\u00e9patotoxicit\u00e9 et \u00e0 des troubles digestifs ou neuropsychiques. Le g\u00e9fapixant, traitement de la toux chronique r\u00e9fractaire dans l\u2019<a href=\"https:\/\/www.20minutes.fr\/dossier\/ue\" target=\"_blank\" class=\"c-link c-link--is-underlined\" rel=\"noopener\">Union europ\u00e9enne<\/a>, s\u2019accompagne de troubles du go\u00fbt tr\u00e8s fr\u00e9quents ainsi que de risques de pneumonies et des troubles urinaires.<\/p>\n<p><a href=\"https:\/\/www.20minutes.fr\/sante\/\" target=\"_blank\" class=\"c-link c-btn c-btn--primary\" rel=\"noopener\">Notre dossier Sant\u00e9<\/a><\/p>\n<p>En r\u00e9visant sa liste chaque ann\u00e9e, Prescrire entend rappeler que la disponibilit\u00e9 d\u2019un m\u00e9dicament ne garantit pas son int\u00e9r\u00eat th\u00e9rapeutique. Pour la revue, l\u2019objectif reste inchang\u00e9\u00a0: fournir une \u00e9valuation ind\u00e9pendante des risques afin de guider des choix de soin plus s\u00fbrs et mieux fond\u00e9s.<\/p>\n","protected":false},"excerpt":{"rendered":"La revue Prescrire publie son nouveau bilan des m\u00e9dicaments \u00ab\u00a0\u00e0 \u00e9carter\u00a0\u00bb, un outil destin\u00e9 \u00e0 aider les patients&hellip;\n","protected":false},"author":2,"featured_media":587189,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[47,1011,27,72,225,4510,71,4984,227],"class_list":{"0":"post-587188","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-actualite","9":"tag-fr","10":"tag-france","11":"tag-health","12":"tag-medicament","13":"tag-risque","14":"tag-sante","15":"tag-soins","16":"tag-traitement"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115686172606936969","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/587188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=587188"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/587188\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/587189"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=587188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=587188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=587188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}